<DOC>
	<DOC>NCT02840110</DOC>
	<brief_summary>Subjects treated with ACTR087 may participate in this long-term follow-up study after the completion of the final scheduled visit in the parent clinical study or other investigational setting, such as compassionate use, named patient IND, expanded access program, or equivalent setting. No investigational product or treatment will be administered in this study. These subjects will be followed for safety monitoring on a schedule of decreasing frequency through 15 years post-ACTR087 treatment, in accordance with US FDA Regulatory guidance pertaining to long-term safety follow-up for study subjects receiving recombinant DNA-containing investigational products.</brief_summary>
	<brief_title>Long-Term Follow-Up Study of Clinical Study Subjects Treated With ACTR087</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma, B-Cell</mesh_term>
	<criteria>Willing to provide informed consent for participation in the study Treated with ACTR087 in an investigational setting If treated with ACTR087 in an interventional clinical study, has completed study assessments and followup visits in the parent study to the extent willing and able to do so If treated with ACTR087 in other investigational settings, such as compassionate use, named patient IND, expanded access program, or equivalent settings, has completed all assessments and follow up visits in that setting to the extent willing and able to do so Able to comply with study requirements</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>